Trial Profile
Evaluation of Safety, Tolerability, Immunogenicity and Efficacy of a Novel Method in Specific Immunotherapy in Cat Allergic Patients: a Placebo Controlled Trial
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Feb 2010
Price :
$35
*
At a glance
- Drugs IVN 201 (Primary)
- Indications Allergic rhinitis
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 17 Feb 2010 Actual end date changed from Mar 2009 to Feb 2010 as reported by ClinicalTrials.gov.
- 19 Mar 2009 Results have been reported in an ImVisioN media release.
- 19 Mar 2009 Status changed from recruiting to completed, as reported in an ImVisionN media release.